Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRPF1 | P55201 | 4/20 | 0.46 |
| ▸ | BRD1 | O95696 | 2/20 | 0.45 |
| ▸ | BRPF3 | Q9ULD4 | 2/20 | 0.45 |
| ▸ | SLC22A12 | Q96S37 | 10/20 | 0.44 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.41 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.41 |
| ▸ | PPARG | P37231 | 2/20 | 0.41 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13629428 | 0.87 | SLC22A12 (0.48) | BRPF1BRD1BRPF3SLC22A12SMARCA2 | |
| SCHEMBL13629411 | 0.84 | PPARG (0.55) | PPARGCYP3A4 | |
| SCHEMBL13629290 | 0.84 | BRD4 (0.52) | PPARG | |
| SCHEMBL13615237 | 0.84 | SLC22A12 (0.47) | BRPF1BRD1BRPF3SLC22A12TRPV4 | |
| SCHEMBL13629338 | 0.80 | SLC22A12 (0.53) | SLC22A12 | |
| SCHEMBL13629408 | 0.80 | CDK1 (0.51) | SLC22A12PPARGCYP3A4 | |
| SCHEMBL13629296 | 0.77 | ALDH1A1 (0.57) | — | |
| SCHEMBL94461 | 0.76 | SLC22A12 (0.48) | SLC22A12PPARGPIK3C3CYP3A4 | |
| SCHEMBL13629312 | 0.76 | ALDH1A1 (0.58) | SLC22A12 | |
| SCHEMBL13615230 | 0.75 | SLC22A12 (0.48) | BRPF1BRD1BRPF3SLC22A12PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090275593-A1 | 3 Substituted N-(aryl- or heteroaryl)-pyrazolo[1,5-a]pyrimidines as Kinase Inhibitors | NOVARTIS AG | 2009-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275593-A1 | 3 Substituted N-(aryl- or heteroaryl)-pyrazolo[1,5-a]pyrimidines as Kinase Inhibitors | TIE1, TEK, MATK | BRPF1 3189/4885BRD1 1062/4885BRPF3 312/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.